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PValvular Heart Disease
Usefulness of the Valvuloarterial
Impedance to Predict Adverse Outcome
in Asymptomatic Aortic Stenosis
Zeineb Hachicha, MD, Jean G. Dumesnil, MD, Philippe Pibarot, DVM, PHD
Québec City, Québec, Canada
Objectives This study was designed to examine the prognostic value of valvuloarterial impedance (Zva) in patients with aor-
tic stenosis (AS).
Background We previously showed that the Zva is superior to standard indexes of AS severity in estimating the global hemo-
dynamic load faced by the left ventricle (LV) and predicting the occurrence of LV dysfunction. This index is calcu-
lated by dividing the estimated LV systolic pressure (systolic arterial pressure  mean transvalvular gradient) by
the stroke volume indexed for the body surface area.
Methods We retrospectively analyzed the clinical and echocardiographic data of 544 consecutive patients having at least
moderate AS (aortic jet velocity 2.5 m·s1) and no symptoms at baseline. The primary end point for this study
was the overall mortality regardless of the realization of aortic valve replacement (AVR).
Results Four-year survival was significantly (p  0.001) lower in the patients with a baseline Zva 4.5 mm Hg·ml1·m2
(65  5%) compared with those with Zva between 3.5 and 4.5 mm Hg·ml
1·m2 (78  4%) and those with Zva
3.5 mm Hg·ml1·m2 (88  3%). The risk of mortality was increased by 2.76-fold in patients with Zva 4.5
mm Hg·ml1·m2 and by 2.30-fold in those with a Zva between 3.5 and 4.5 mm Hg·ml
1·m2 after adjusting for
other risk factors and type of treatment (surgical vs. medical).
Conclusions Increased Zva is a marker of excessive LV hemodynamic load, and a value 3.5 successfully identifies patients
with a poor outcome. These findings suggest that beyond standard indexes of stenosis severity, the consider-
ation of Zva may be useful to improve risk stratification and clinical decision making in patients with AS.
(J Am Coll Cardiol 2009;54:1003–11) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.079(
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5educed arterial compliance is a frequent occurrence in
atients with degenerative aortic stenosis (AS), where it
ndependently contributes to increase afterload and decrease
eft ventricular (LV) function (1,2). Congenital bicuspid AS
s also associated with impaired aortic elasticity, indepen-
ent of stenosis severity or aortic size (3,4). Hence, the LV
f AS patients often faces a double load: valvular plus
rterial, and in these patients, the presence of symptoms and
ccurrence of adverse events should logically better correlate
ith the global burden faced by the ventricle than with the
ransvalvular gradient and/or aortic valve area (AVA). To
his effect, we recently proposed a new index of global LV
emodynamic load, that is, the valvuloarterial impedance
rom the Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec
eart and Lung Institute, Department of Medicine, Laval University, Québec City,
uébec, Canada. This work was supported by a grant from the Canadian Institutes
f Health Research (MOP-82873), Ottawa, Canada. Dr. Pibarot holds the Canada
esearch Chair in Valvular Heart Diseases, Canadian Institutes of Health Research,
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Manuscript received December 2, 2008; revised manuscript received March 20,
009, accepted April 21, 2009.Zva), which is calculated by dividing the estimated LV
ystolic pressure (systolic arterial pressure  mean transval-
ular gradient) by the stroke volume index (SVI) (1). This
ndex, in fact, represents the cost in mm Hg for each
ystemic milliliter of blood indexed for the body size,
See page 1012
umped by the LV during systole. And, indeed, we have
hown that Zva is superior to the standard indexes of AS
everity in predicting LV dysfunction (1). The objective of
his study was to examine the relevance of Zva with regard
o prognosis, and in particular, to define reference values
hat could be used in routine clinical practice.
ethods
atient population. We retrospectively reviewed the clinical
nd echocardiographic data that were prospectively collected in
44 asymptomatic patients (320 men and 224 women; mean
ge 70  14 years; range 21 to 98 years) with at least a
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tic jet velocity 2.5 m·s1. The
exclusion criteria were concomi-
tant moderate or severe aortic in-
sufficiency or mitral valve disease,
left ventricular ejection fraction
(LVEF) 50%, and the presence
of symptoms at baseline.
Clinical data. Clinical data in-
cluded age, sex, history of smok-
ing, documented diagnosis of hy-
pertension, hypercholesterolemia,
diabetes, obesity (body mass index
30 kg/m2), and coronary heart
disease (5).
Systemic arterial hemodynam-
ics. Systemic arterial pressure
was measured with the use of an
arm cuff sphygmomanometer at
the same time as the Doppler
measurement of stroke volume
SV) was measured in the left ventricular outflow tract. The
atio of SVI to brachial pulse pressure (PP) was used as an
ndirect measure of total systemic arterial compliance:
AC  SVI/PP (1). The systemic vascular resistance was
stimated by the formula: SVR  (80 MAP)/CO, where
AP is the mean arterial pressure defined as diastolic
ressure plus one-third of PP and CO is the cardiac output.
oppler echocardiographic data. AORTIC VALVE STENO-
IS SEVERITY. The Doppler echocardiographic indexes of
S severity included: the mean transvalvular pressure
radient obtained with the use of the modified Bernoulli
quation, the AVA obtained with the use of the standard
ontinuity equation, and the energy loss index (ELI) as
reviously described in Garcia et al. (6). Severe AS was
efined as an AVA 1.0 cm2.
V GEOMETRY. Two-dimensionally directed LV M-mode di-
ensions were measured in the left parasternal long-axis view
ollowing the recommendations of the American Society of
chocardiography. Left ventricular minor axis internal dimension
LVID), posterior wall thickness (PWT), and interventricular
eptal thickness (IVST) were measured at end-diastole (d). The
V mass was calculated using the corrected formula of the
merican Society of Echocardiography and was indexed for body
urface area. Significant LV hypertrophy was defined as LVmass
ndex134 g/m2 inmen and110 g/m2 in women. The relative
all thickness (RWT) was calculated with the formula: RWT
PWTd  IVSTd)/LVIDd.
V SYSTOLIC FUNCTION. Diastolic function was assessed as
reviously described (7). The LVEF was determined in all
atients using the Quinones method, the Dumesnil method
8), and visual estimate. In the case of a disagreement
mong these methods, the reviewing cardiologist selected
Abbreviations
and Acronyms
AS  aortic stenosis
AVA  aortic valve area
AVR  aortic valve
replacement
CABG  coronary artery
bypass graft
CI  confidence interval
ELI  energy loss index
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
PP  pulse pressure
SV  stroke volume
SVI  stroke volume index
Zva  valvuloarterial
impedancehe value that seemed the most representative.
vLOBAL LV HEMODYNAMIC LOAD. As a measure of global
V load, we calculated the valvuloarterial impedance: Zva
SAP  MG)/SVI, where SAP is the systolic arterial
ressure and MG is the mean transvalvular pressure gradi-
nt (1). Hence, Zva represents the valvular and arterial
actors that oppose ventricular ejection by absorbing the
echanical energy developed by the LV.
linical outcomes. The primary end point for this study
as overall death regardless of whether or not there was
ortic valve replacement (AVR). Hence, this includes the
eaths occurring in patients who did not undergo AVR as
ell as those occurring after operation in patients who
nderwent AVR. The outcome data were retrospectively
btained from patients’ charts or death certificates.
tatistical analysis. We subdivided the patients into 3
roups according to the level of Zva: 1) Zva 3.5 mm
g·ml1·m2 (low Zva group, n  172; 32%); 2) 3.5  Zva
4.5 mm Hg·ml1·m2 (medium Zva group, n  192;
5%); and 3) Zva 4.5 mm Hg·ml
1·m2 (high Zva group,
 180, 33%). These 3 groups correspond approximately
o the tertiles of Zva.
Continuous data were expressed as mean  SD and
ompared among the 3 Zva groups using a 1-way analysis of
ariance followed by a Tukey test. Categorical data were
iven as a percentage and compared with a chi-square test.
umulative probability of survival was estimated with the
aplan-Meier method and compared between groups using
log-rank test. The survival observed in these groups was
lso compared with that of the general population in the
uébec province matched for age and sex. The survival data
f this control population were derived from the 2002 life
ables of Canada Statistics. The effect of the clinical and
oppler echocardiographic variables on survival was as-
essed with the use of a Cox proportional hazards model. All
f the variables presented in Tables 1, 2, and 3 as well as the
ype of treatment (medical vs. surgical, i.e., AVR) were
ested in univariate analysis, and those with a p value 0.20
n univariate analysis were incorporated into the multivar-
ate models. Age was forced into the model. To avoid
olinearity among a subset of several variables measuring the
aseline Clinical Characteristicsf the Patie ts According to the Level of ZvaTable 1 Baseline Clinical Characteristicsof the Patients According to the Level of Zva
Group
Low Zva
(n  172)
Medium Zva
(n  192)
High Zva
(n  180) p Value
Age, yrs 66 15 70 12* 73 13*† 0.001
Female sex 69 (40) 73 (38) 82 (46) NS
Body surface area, m2 1.8 0.2 1.8 0.2 1.8 0.2 NS
Body mass index, kg/m2 27 6 27 5 28 5 NS
Obesity 39 (23) 53 (27) 55 (31) NS
Hypertension 96 (56) 138 (72)* 128 (71)* 0.02
Hypercholesterolemia 93 (54) 109 (57) 76 (42) NS
Diabetes 39 (23) 40 (21) 34 (19) NS
Coronary artery disease 96 (56) 128 (67) 106 (59) NS
alues aremean SD or n (%). *Significant difference versus low Zva group. †Significant difference
ersus medium Zva group.
NS  not significant; Zva  valvuloarterial impedance.
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September 8, 2009:1003–11 Valvuloarterial Impedance in Aortic Stenosisame phenomenon (e.g., AVA, peak gradient, mean gradi-
nt, ELI), we entered in the multivariate models the
ariable that had the strongest association with mortality on
nivariate analysis. We constructed a first series of multi-
ariate models with independent variables entered in con-
inuous format and then a second series with these variables
ntered in dichotomous formats.
esults
able 1 shows the baseline characteristics of the patients in
he 3 Zva groups. Patients with high and medium Zva were
Doppler Echocardiographic and Systemic ArteriaArterial Load, n Global LV Hemodynamic LoadTable 2 Doppler Echo ardiographic and SysArterial Load, and Global LV Hemod
Group
L
(n
Valvular load
Aortic valve area, cm2 1
Aortic valve area index, cm2·m2 0.6
Energy loss index, cm2·m2 0.7
Peak gradient, mm Hg 4
Mean gradient, mm Hg 2
Vascular load
Systolic arterial pressure, mm Hg 12
Diastolic arterial pressure, mm Hg 6
Systemic arterial compliance, ml·m2·mm Hg1 0.9
Systemic vascular resistance, dyne·s·cm5 1,30
Global LV hemodynamic load
Valvuloarterial impedance, mm Hg·ml1·m2 3
*Significant difference versus low Zva group. †Significant difference v
LV  left ventricular; other abbreviation as in Table 1.
Doppler Echocardiographic Data ofLV Geometry and Function According to the LTable 3 Doppler Ech ardiographic Data oLV Geometry and Function Accord
Group
Low Zva
(n  172
LV geometry
IVSTd, mm 12 3
PWTd, mm 10 2
LVIDd, mm 48 5
LVEDV, ml 111 27
LVEDV index, ml·m2 61 13
Relative wall thickness, % 44 10
LV mass, g 210 73
LV mass index, g/m2 116 34
LV systolic function
LV ejection fraction, % 67 7
Stroke volume, ml 87 16
Stroke volume index, ml·m2 48 8
Cardiac output, l·min1 5.5 1.2
Cardiac index, l·min1·m2 3.1 0.7
Mean transvalvular flow rate, ml·s1 268 61
LV diastolic function, %
Normal 20
Abnormal 80
*Significant difference versus low Zva group. †Significant difference v
IVSTd interventricular septal thickness in diastole; LVEDV left ventricula
diastole; PWTd  posterior wall thickness in diastole; other abbreviations asignificantly older and had a higher prevalence of systemic
rterial hypertension compared with those with low Zva.
here was no significant difference among the 3 groups with
egard to sex distribution, body surface area, body mass
ndex, and prevalence of hypercholesterolemia, diabetes, and
oronary artery disease.
Table 2 shows the data of the Doppler echocardiographic
nd systemic arterial indexes reflecting the valvular load (i.e.,
S severity) and the arterial load. As expected, patients with
igh Zva had a higher valvular load, that is, more severe
alvular stenosis, as reflected by smaller AVA and ELI and
exes of Valvular Load,ording to the Level of ZvaArterial Index s f Valvular Load,
ic Load According to the Level of Zva
a
2)
Medium Zva
(n  192)
High Zva
(n  180) p Value
.2 1.0 0.3* 0.8 0.2*† 0.0001
.13 0.56 0.15* 0.45 0.12*† 0.0001
.18 0.65 0.23* 0.51 0.15*† 0.0001
6 46 20 56 26*† 0.0001
0 27 12 34 17*† 0.0001
6 135 19* 145 23*† 0.001
73 10* 78 10*† 0.0001
.24 0.69 0.18* 0.57 0.18*† 0.0001
87 1,605 361* 1,824 398*† 0.001
.4 4.0 0.3* 5.2 0.9*† 0.0001
edium Zva group.
of Zva
o the Level of Zva
Medium Zva
(n  192)
High Zva
(n  180) p Value
12 2 13 3*† 0.001
11 2 11 2* 0.02
47 5 45 5*† 0.001
106 27 96 25*† 0.001
58 13* 52 12*† 0.001
46 10* 49 10*† 0.001
209 56 210 64 NS
114 27 115 32 NS
66 7 65 7* 0.025
75 12* 65 15*† 0.001
41 5* 35 7*† 0.001
4.8 1.0* 4.6 1.1*† 0.001
2.6 0.5* 2.5 0.5*† 0.001
232 49* 210 55*† 0.001
13 11 NS
87 89 0.001
edium Zva group.l IndAcctemic
ynam
ow Zv
 17
.2 0
6 0
8 0
4 1
5 1
2 1
8 9
4 0
3 2
.1 0evelf
ing t
)
ersus m
r end-diastolic volume; LVIDd left ventricular internal dimension in
in Tables 1 and 2.
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Valvuloarterial Impedance in Aortic Stenosis September 8, 2009:1003–11igher transvalvular gradients compared with patients with
edium or low Zva (Fig. 1). Patients with medium Zva also
ad significantly smaller AVA but similar gradients compared
ith patients with low Zva. Patients with higher levels of Zva
lso had a higher vascular load as reflected by reduced systemic
rterial compliance, increased systemic vascular resistance, and
igher systolic and diastolic arterial pressures.
Table 3 shows the echocardiographic data of LV geom-
try and function. Patients in the high Zva group had thicker
V walls, a smaller LV cavity, and a higher relative wall
hickness ratio compared with those in the medium and low
va groups. Patients with high Zva also had a lower LVEF,
V, cardiac output, and mean transvalvular flow rate com-
ared with patients with lower Zva. The indexes of LV
ystolic function, except LVEF, were also significantly lower
n the medium Zva group than in the low Zva group.
Moreover, as shown in Figure 1, the proportion of
atients with a paradoxical low flow pattern, defined as
toke volume index 35 ml·m2 in the setting of LVEF
50%, was much higher (p  0.001) in the high Zva group
n  90, 50%) than that in the medium Zva group (n  28,
5%) or in the low Zva group (n  7, 4%), which is
Figure 1 Distribution of Stenosis Severity
and Paradoxical Low-Flow Pattern Versus Zva
Percentage of patients with moderate versus severe aortic stenosis (AS) (A)
and with normal flow (NF) versus paradoxical low flow (PLF) (B) according to
the level of valvuloarterial impedance (Zva) (low Zva 3.5, moderate 3.5 Zva
4.5, high Z 4.5). The numbers in the bars are percentages.p
vaonsistent with our previous study showing that patients
ith paradoxical low flow are characterized by a markedly
ncreased Zva (5). Hence, among the 125 patients with
aradoxical low flow, 90 (72%) had a high Zva, and of these
atients 74 (82%) had a severe AS.
ype of treatment. Aortic valve replacement was per-
ormed during follow-up in 54 (31%) patients in the low Zva
roup, 58 (30%) in the medium Zva group, and 64 (36%) in
he high Zva group. Coronary artery bypass grafting
CABG) was performed concomitantly in 75 of 176 (43%)
atients. Among the 176 patients undergoing AVR, 166
94%) had severe AS at the time of operation (67 of these
atients underwent CABG) and 10 (6%) had moderate AS
8 underwent CABG).
linical outcome. The mean follow-up time in the total
ohort was 2.5  1.8 years (median 2.1 years). The
ollow-up was complete in all patients, and there was no
ignificant difference between groups with regard to the
uration of follow-up.
Overall, there were 91 deaths: 15 (9%) in the low Zva
roup, 36 (19%) in the medium Zva group, and 40 (22%) in
igh Zva group. Among them 51 (56%) were from a
ardiovascular cause: 7 (4%) in low Zva group, 19 (10%) in
he medium Zva group, and 25 (14%) in the high Zva group.
eventy-eight of the 91 deaths occurred in patients treated
edically, whereas 13 occurred after AVR. Six of these
ost-operative deaths occurred in the early post-operative
eriod (30 days).
Four-year survival was significantly (p  0.001) lower in
he high Zva group (65  5%) than in the medium (78 
%) and low (88  3%) Zva groups. Survival was also
ignificantly (p  0.007) lower in the patients with medium
va compared with those with low Zva (Fig. 2). Patients
ith low Zva had similar survival compared with that of the
eneral population in Quebec, whereas patients in the
edium and high Zva groups had lower (p  0.05) survival
han in this control population.
Figure 3 shows the survival as a function of the 3 levels of
va and the type of treatment. Particularly noteworthy is the
act that survival of patients in the 3 groups treated
urgically was similar or better than that of the control
opulation, albeit there was a statistical difference (p 
.02) between the high and low Zva groups treated surgi-
ally. Likewise, survival of patients in the low Zva group
reated medically was no different from that of the control
opulation. Conversely, patients with high and moderate
va treated medically had markedly lower survival compared
ith the control population (p  0.002 and p 0.002,
espectively) and with the patients with low Zva (p 0.0003
nd p  0.02, respectively). Moreover, although signifi-
antly different in both groups, the magnitude of the
rotective effect of AVR was most important in patients
ith higher Zva (4-year survival: 87  5% vs. 42  9% for
atients treated medically, p  0.001) than in patients with
oderate Zva (4-year survival: 89  5% vs. 74  4% for
atients treated medically, p 0.001). Overall, these results
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September 8, 2009:1003–11 Valvuloarterial Impedance in Aortic Stenosiseem to identify Zva 3.5 mm Hg·ml
1·m2 as the logical
hreshold to identify patients likely to be at higher risk if
reated medically rather than surgically.
redictors of outcome. Table 4 shows the univariate and
ultivariate predictors of mortality. Mortality risk increased by
.41-fold (95% confidence interval [CI]: 1.17 to 1.67, p 
.0004) per 1-U increase in Zva on univariate analysis and by
.36-fold (95% CI: 1.03 to 1.75, p  0.03) on multivariate
nalysis (Model 1 in Table 4). When Zva was expressed in
categorical format, a value of Zva 4.5 mm Hg·ml
1·m2
as associated with a hazard ratio for mortality of 2.95 (95%
I: 1.67 to 5.53, p  0.0001), whereas a value of Zva 3.5
nd 4.5 mm Hg·ml1·m2 was associated with a hazard
atio of 2.24 (95% CI: 1.25 to 4.22, p  0.006). On
ultivariate analysis, the independent risk factors for mor-
ality were older age, increased LV mass index, and in-
reased Zva, whereas the surgical treatment (AVR with or
ithout CABG) was highly protective (models 1 and 2 in
able 4). The risk of mortality was increased by 2.76-fold
95% CI: 1.32 to 5.92; p  0.01) in patients with Zva 4.5
m Hg·ml1·m2 and by 2.30-fold (95% CI: 1.16 to 4.71;
 0.03) in those with a Zva comprised between 3.5 and
.5 mm Hg·ml1·m2 after adjustment for other risk factors
nd type of treatment (surgical vs. medical) (Model 2 in
Figure 2 Overall Survival Versus Zva
Overall survival as a function of the level of valvuloarterial impedance (Zva) (low Zv
high Zva 4.5 [red line]). Survival was compared with that in the general populatioable 4). With regard to the risk of cardiovascular mortality, svalue of Zva 4.5 mm Hg·ml
1·m2 was associated with a
azard ratio for mortality of 3.71-fold (95% CI: 1.47 to
0.17; p  0.001) whereas a value of Zva 3.5 and 4.5
m Hg·ml1·m2 was associated with a hazard ratio of 3.11
95% CI: 1.28 to 8.20, p  0.014).
iscussion
he most important finding of the present study is that Zva
redicts adverse outcome in asymptomatic patients with at
east moderate AS, even after adjustment for standard
ndexes of stenosis severity, LV geometry and function, and
ype of treatment. A value of Zva 4.5 mm Hg·ml
1·m2
as indeed associated with a 2.76- and a 3.71-fold increase
n the risk of overall and cardiovascular mortality, respec-
ively, whereas a value of Zva between 3.5 and 4.5 was
ssociated with 2.30- and 3.11-fold increases of the same
isks. The fact that the adverse impact of Zva on survival was
ost evident in patients with moderately (3.5 and 4.5
m Hg·ml1·m2) or severely (4.5 mm Hg·ml1·m2)
ncreased Zva treated medically whereas survival of patients
reated surgically or with a low Zva (3.5 mm Hg·ml
1·m2)
as similar or better than that of the general population in
uebec is also compelling evidence that this parameter
[green line], moderate 3.5  Zva 4.5 [blue line],
uebec matched for age and sex (control group; black line).a 3.5
n in Qhould be highly useful for risk stratification and clinical
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Valvuloarterial Impedance in Aortic Stenosis September 8, 2009:1003–11ecision making and that the logical reference value for this
urpose would seem to be a Zva 3.5 mm Hg·ml
1·m2.
The valvuloarterial impedance provides an estimate of the
lobal LV hemodynamic load that results from the summa-
ion of the valvular and vascular loads, and the concept is
ery useful because it incorporates stenosis severity, volume
ow rate, body size, and systemic vascular resistance. More-
ver, Zva can easily be calculated using Doppler echocar-
iography from 3 simple measurements, that is, the SVI in
he LV outflow tract, the transvalvular mean gradient, and
ystolic arterial pressure, and as previously shown (1), it is
uperior to the standard indexes of AS severity in predicting
V dysfunction. These results have been independently cor-
oborated by a substudy of the SEAS (Simvastatin and
zetimibe in Aortic Stenosis) trial (9), in which increased Zva
as a powerful independent predictor of myocardial systolic
ysfunction in asymptomatic patients with mild to severe AS.
oreover, in a recent study (5) including only patients with
evere AS, a value of Zva5.5 mmHg·ml
1·m2 was associated
ith a 2.5-fold increase in the risk of overall mortality,
egardless of the type of treatment (AVR or medical). An
mportant limitation of that study, however, is that many
Figure 3 Overall Survival Versus Zva and Type of Treatment
Overall survival as a function of the level of valvuloarterial impedance (Zva) (low Zva 
the type of treatment: medical (solid lines) versus surgical (dashed lines). Survival wa
trol group; black line).atients were already symptomatic at baseline. womparison with previous studies. Previous studies of
atients with asymptomatic AS have identified older age,
emodynamic severity of AS, severe aortic valve calcifi-
ation, physical inactivity, coronary artery disease, and
enal failure as independent predictors of adverse events
enerally defined as AVR (or onset of symptoms) and
eath (10–12). In the present study, we identified some
f these factors, such as age and baseline AVA, as
redictors of mortality. It should also be emphasized that
va was not determined in previous studies. Moreover, we
elected overall mortality as the end point for the present
tudy rather than a combined end point of AVR or death as
sed in some previous studies.
S: a disease not only limited to the valve. There is now
strong body of evidence suggesting that degenerative AS is
n active disease akin to atherosclerosis (13,14), and in this
ontext, it is not surprising that many patients with degen-
rative AS also have manifestations of atherosclerosis in
ther target organs. Many patients with degenerative AS
hus also may present with concomitant systolic hyperten-
ion, and indeed, a markedly reduced arterial compliance
as previously found to be present in up to 40% of patients
een lines], moderate 3.5  Zva 4.5 [blue lines], high Zva 4.5 [red lines]) and
pared with that in the general population in Quebec matched for age and sex (con-3.5 [gr
s comith at least moderate AS (1). As well, such patients also
m
c
a
d
A
t
i
a
s
a
b
w
r
e
p
i
e
r
f
e
t
a
m
c
t
o
o
b
t
w
o
u
i
C
f
i
a
a
m
L
a
b
p
A
o
r
m
(
o
e
o
m
a
icular e
1009JACC Vol. 54, No. 11, 2009 Hachicha et al.
September 8, 2009:1003–11 Valvuloarterial Impedance in Aortic Stenosisay have alterations of LV function that might not only be
aused by AS as such but also by hypertension and/or
ssociated coronary artery disease and in varying proportions
epending on the severity of each entity. Thus, degenerative
S cannot be viewed as an isolated disease strictly limited to
he valve, but rather as part of a continuum that may also
nclude a reduction in systemic arterial compliance and/or
lterations of LV function. From the results of the present
tudy, it would indeed seem that the pathophysiology of
dverse outcomes in AS is primarily related to an imbalance
etween the global increase in LV overload, independent of
hether it be of valvular and/or vascular origin, and LV
eserve both at rest and during exercise; as well, it becomes
vident that Zva is the best-suited and most relevant
arameter to clinically quantify this “global or total” increase
n LV hemodynamic load.
The chronic exposure to a high level of afterload may
ventually lead to a reduction in the coronary vasodilatory
eserve, an intrinsic impairment of myocardial contractile
unction, and a decrease in cardiac output (1,5,9,15). To this
ffect, previous studies from our laboratory (1,5) and from
he SEAS investigators (9) have reported that patients with
markedly increased Zva often have decreases in LVEF,
id-wall fractional shortening, and cardiac output. The
onsequences of a reduction in cardiac output are a reduc-
ion of transvalvular gradients and a pseudo-normalization
f peripheral blood pressure, which may occur in up to 30%
Univariate and Multivariate Analysis of Predictoof Over ll Death in the Total Cohort (544 PatienTable 4 Univariat and Multivariate Analysisof Overall Death in the Total Cohort
Univar
p Value
Model 1: continuous
Age, yrs 0.0001
Hypertension 0.007
AVA, cm2 0.0015
LVEF, % 0.02
SAC, ml·m2·mm Hg1 0.0004
LVMI, g/m2 0.0016
Zva, mm Hg·ml
1·m2 0.0004
Surgical treatment 0.0001
Model 2: categorical
Age 70 yrs 0.0001
Hypertension 0.007
AVA 1.0 cm2 0.015
LVEF 55% 0.005
SAC 0.6 ml·m2·mm Hg1 0.026
LV hypertrophy 0.03
Zva 3.5 mm Hg·ml
1·m2 —
3.5  Zva 4.5 mm Hg·ml
1·m2 0.006
Zva 4.5 mm Hg·ml
1·m2 0.0001
Surgical treatment 0.0001
For model 1, all variables except hypertension and surgical treatmen
increase in mortality risk per 1-U increase in the variable. For model 2
AVA  aortic valve area; CI  confidence interval; LVEF  left ventr
arterial compliance; other abbreviations as in Table 1.f patients (1,5). Clinically, this situation is highly insidious because both AS and hypertension may appear less severe on
he basis of the transvalvular gradients and blood pressure,
hereas, in fact, these patients are at a more advanced stage
f their disease. In this regard, the calculation of Zva may be
seful for identifying the patients in whom disease severity
s masked by this pseudo-normalization phenomenon.
linical implications. These results strengthen the need
or a more comprehensive evaluation of AS that should
nclude indexes such as: 1) AVA and ELI (in patients with
small aorta) for the assessment of valvular load; 2) systemic
rterial compliance and vascular resistance for the assess-
ent of arterial load; and finally, 3) Zva to quantify global
V load. The consideration of these indexes easily measur-
ble by Doppler echocardiography allows the clinician to
etter quantify the severity of the disease and could be
articularly helpful in the 3 following clinical situations.
SYMPTOMATIC PATIENTS WITH SEVERE AS. Management
f these patients remains a source of debate (16,17), and
ecent studies have suggested that those treated surgically
ay have better survival than those treated medically
18–20). This difference may be related to underestimation
f symptoms and/or stenosis severity in some patients,
specially in the elderly sedentary patients (5,19,20). More-
ver, it has been argued that a “wait for symptoms” strategy
ay result in some patients undergoing surgery too late (i.e.,
t a stage of the disease when myocardial impairment has
redictors
Patients)
nalysis Multivariate Analysis
HR (95% CI) p Value HR (95% CI)
7 (1.04–1.09) 0.0002 1.05 (1.02–1.08)
7 (1.19–3.44) NS —
0 (0.14–0.64) NS —
7 (0.94–0.99) NS —
9 (0.07–0.49) NS —
1 (1.00–1.02) 0.004 1.01 (1.01–1.02)
1 (1.17–1.67) 0.03 1.36 (1.03–1.75)
1 (0.11–0.38) 0.0001 0.22 (0.11–0.43)
6 (2.31–6.87) 0.0001 2.94 (1.50–6.17)
7 (1.19–3.44) NS —
7 (1.10–2.54) NS —
3 (1.29–3.65) NS —
0 (1.05–2.42) NS —
5 (1.03–2.59) 0.05 1.66 (1.01–2.73)
0 (referent) — 1.00 (referent)
4 (1.25–4.22) 0.03 2.30 (1.16–4.71)
5 (1.67–5.53) 0.01 2.76 (1.32–5.92)
1 (0.11–0.38) 0.0001 0.20 (0.10–0.36)
entered in continuous format. The hazard ratio (HR) represents the
riables were entered in a dichotomous format.
jection fraction; LVMI  left ventricular mass index; SAC  systemicrsts)of P
(544
iate A
1.0
1.9
0.3
0.9
0.1
1.0
1.4
0.2
3.8
1.9
1.6
2.2
1.6
1.6
1.0
2.2
2.9
0.2
t were
, all vaecome, at least in part, irreversible) (21). On the other
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Valvuloarterial Impedance in Aortic Stenosis September 8, 2009:1003–11and, AVR is not without risk (22), and the decision to
perate on such patients therefore requires careful weigh-
ng of benefits against risks. To this effect, Zva may be
seful for identifying patients who are at higher risk and
ay be an indication for closer follow-up and further
nvestigation. In this context, exercise stress testing may
e particularly useful to corroborate symptomatic status
n patients with a Zva 4.5 mm Hg·ml
1·m2 who claim
o be asymptomatic. If the exercise test is abnormal
exercise-limiting symptoms, decrease in blood pressure),
VR can be contemplated (16), whereas in the case of a
ormal test, the patient can be followed up more closely
ith a clinical brain natriuretic peptide level and/or
chocardiographic evaluation every 6 to 12 months (23).
YMPTOMATIC PATIENTS WITH MODERATE AS. Patients
ith moderate AS may become symptomatic because of
oncomitant hypertension. The calculation of Zva may thus
elp to reconcile the apparent discrepancy between stenosis
everity and symptomatic status. If the Zva is 3.5 mm
g·ml1·m2, the symptoms could be related to a concom-
tant disease such as coronary artery disease, whereas if it is
3.5 mm Hg·ml1·m2, the symptoms could be caused by
he additive effects of the moderate AS and reduced arterial
ompliance and/or increased vascular resistance.
In such patients, the logical first step would be to treat
heir hypertension and then to re-evaluate symptomatic
tatus and Zva under treatment. Traditionally, vasodilator
herapy has been considered relatively contraindicated in
atients with AS because of its hypotensive effects, but
ecent studies, however, suggest that except in patients with
ery severe disease, it can be applied both safely and
eneficially (23,24). Nonetheless, therapy should be intro-
uced cautiously, particularly in patients with severe AS.
urther studies will, however, be necessary to determine
hether symptomatic status and outcome can be signifi-
antly improved in this fashion. Indeed, because AS patients
ften have reduced arterial compliance (1), blood pressure
evels may not be completely normalized by treatment.
ARADOXICAL LOW-FLOW, LOW-GRADIENT, SEVERE
S. We recently reported that an important proportion of
he patients with severe AS on the basis of AVA paradox-
cally have a low transvalvular flow rate (SVI 35 ml/m2)
nd thus a low gradient (40 mm Hg) despite the presence
f a preserved LVEF (50%) (5). When compared with
atients with severe AS, normal LV output and thus high
radient, these patients with paradoxical low flow were
haracterized by a higher degree of LV concentric remod-
ling, a lower LVEF (although still within the normal
ange), a reduced mid-wall shortening, a markedly higher
evel of LV global load reflected by a higher Zva, and a worse
rognosis if treated medically. Hence, it can be conceived
hat a greater and more longstanding increase in afterload
ay result in more pronounced LV concentric remodeling,
smaller LV cavity size, and a decrease in intrinsic myo-
ardial function. This paradoxical low-flow, low-gradient sS pattern may bring some uncertainty about the actual
everity of AS and may lead clinicians to erroneously
onclude that the stenosis is not severe and that surgery is
ot indicated. Hence, the consideration of Zva may be
elpful in these patients to determine the actual level of
lobal LV hemodynamic load that is often underestimated
ecause of a reduction of transvalvular gradients and a
seudo-normalization of arterial pressures inherent to the
ow-flow state. If the Zva is high, it is likely that the
xcessive hemodynamic load imposed by AS and/or
ypertension contributed to the alteration of LV geom-
try and function that, in turn, led to the paradoxical
ow-flow state. In the present series, the vast majority
72%) of patients with paradoxical low flow had high Zva,
nd among these patients 80% had a severe AS. In the
ubset of patients with moderate AS, the severe augmen-
ation of Zva is most likely caused by the coexistence of
ypertension. On the other hand, if Zva is low, the
lteration of the LV geometry and function leading to a
aradoxical low-flow state may be caused by concomitant risk
actors or diseases such as diabetes, metabolic syndrome, or
ypertrophic cardiomyopathy.
tudy limitations. One limitation of this study is its
etrospective design. The baseline data were prospectively
ollected in consecutive patients with asymptomatic AS
eferred to the echocardiographic laboratory. However, the
utcome data were retrospectively obtained from patients’
harts or death certificates. Consequently, we did not have
he information on: 1) the exact timing of symptom onset
uring follow-up; 2) the proportion of patients in whom
evere symptomatic AS developed and who were not re-
erred to AVR because of advanced age, comorbidities, or
nappropriate management; and 3) the primary reason that
otivated AVR. These limitations were, at least in part,
ompensated by the fact that we used overall survival (and
ot AVR) as the primary end point for this study and that
e adjusted for the type of treatment in the multivariate
nalyses.
Patients with more than mild aortic insufficiency were
xcluded from the study. In the presence of significant
ortic insufficiency, both the numerator (transvalvular
radient) and the denominator (SVI measured in the LV
utflow tract) of Zva may increase, which may reduce the
bility of this index to correctly quantify the severity of
he hemodynamic load in patients with mixed valvular
ysfunction, and further studies are thus needed to
xamine the applicability and utility of Zva in patients
ith mixed dysfunction.
onclusions
ncreased Zva is a marker of excessive LV hemodynamic
oad and identifies patients with a poor outcome. These
ndings suggest that beyond standard indexes of stenosis
everity, LV geometry, and function, the consideration of
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ecision making in patients with AS.
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